Jinhe Biotechnology Co Ltd

Jinhe Biotechnology maintains a debt-to-equity ratio of 1.15, indicating a moderate reliance on debt financing. The company's current ratio of 1.07 suggests it has just enough current assets to cover its short-term liabilities, but with little room for operational shocks. Operating cash flow of CNY 169.99 million is positive, but capital expenditures of CNY -159.77 million suggest the company is investing in its operations, potentially to expand production or R&D capabilities.

Profitability metrics show a return on equity (ROE) of 2.07% and a return on assets (ROA) of 0.81%, both of which are below the typical thresholds for high-performing pharmaceutical firms. The company's net income of CNY 45.88 million is modest relative to its total assets of CNY 5.66 billion, indicating that it is not generating strong returns on its capital base.

The company's revenue is concentrated in a single business segment, as disclosed in its financial statements, with no material geographic diversification reported. This lack of diversification increases exposure to regional economic and regulatory risks, particularly in China, where the company is headquartered and operates the majority of its business.

Looking ahead, the company is expected to see a modest increase in revenue, with a projected growth rate of less than 5% in the current fiscal year. This growth is constrained by the competitive nature of the pharmaceutical industry and the high cost of R&D and regulatory compliance. The company's capital expenditures are expected to remain negative, indicating continued investment in infrastructure and production capabilities.

The company faces moderate liquidity risk due to its current ratio of 1.07 and a negative net cash position after subtracting total debt. While dilution risk is currently low, the company has not issued new shares recently, and there is no indication of a pending equity offering. However, the company's debt load remains a concern, as long-term debt of CNY 2.56 billion represents a significant portion of its capital structure.

No recent filings or transcripts have been disclosed that would indicate a material change in the company's strategic direction or financial outlook. The company's most recent financial statements and disclosures suggest a stable but slow-growth trajectory, with no major new product launches or regulatory approvals announced.

Jinhe Biotechnology Co Ltd (002688.SZ) has been formally classified within the Healthcare economic sector, specifically under the Pharmaceuticals & Medical Research activity. This taxonomic update provides a clearer definition of the company’s operational focus, aligning its market identity with its core business functions in the biotechnology and pharmaceutical space. Alongside this classification, the company’s risk profile has been established with a low dilution risk rating. This assessment suggests that the likelihood of significant share dilution is currently minimal, offering a degree of stability for existing shareholders regarding their equity ownership stakes. Conversely, the risk assessment identifies a medium liquidity risk. This indicates that while the company is not facing immediate solvency issues related to dilution, there may be moderate constraints on the ease with which its shares can be traded or converted to cash without impacting the price. The company currently has one analyst covering its performance, though it holds no index memberships and has no reported top holders or officers in the available data. These structural details, combined with the new risk and sector classifications, provide a foundational baseline for evaluating Jinhe Biotechnology’s position in the market. [doc:002688.sz-ha-financials]

Operating and net margins exceed pharmaceutical cohort medians, indicating superior profitability relative to peers.

Revenue grew 21.4% year-over-year, demonstrating strong top-line expansion despite margin pressures.

Cash conversion is best-in-class compared to the pharmaceutical cohort, suggesting efficient working capital management.

Gross profit reached 960 million CNY, providing a substantial buffer for operating expenses.

Free cash flow improved by 6.2% year-over-year, showing slight stabilization in cash generation.

Debt-to-equity ratio of 1.15 is in the bottom quartile, indicating excessive leverage risk.

High credit risk flag suggests significant concerns regarding the company's ability to meet obligations.

Negative free cash flow of 229 million CNY indicates ongoing cash burn despite revenue growth.

Revenue ¥2.08B; Operating income ¥138.4M.

• ▍Revenue ¥2.08B
• ▍Operating income ¥138.4M
• ▍Net margin 4.5%